Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53., PMID:9679054
The cdc25B phosphatase is essential for the G2/M phase transition in human cells., PMID:9683638
Production and characterization of a rabbit monoclonal antibody against human CDC25C phosphatase., PMID:9790074
Involvement of Chk1 kinase in prophase I arrest of Xenopus oocytes., PMID:10068474
Cytoplasmic localization of human cdc25C during interphase requires an intact 14-3-3 binding site., PMID:10330186
A maternal form of the phosphatase Cdc25A regulates early embryonic cell cycles in Xenopus laevis., PMID:10433828
The disappearance of cyclins A and B and the increase in activity of the G(2)/M-phase cellular kinase cdc2 in herpes simplex virus 1-infected cells require expression of the alpha22/U(S)1.5 and U(L)13 viral genes., PMID:10590085
Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity., PMID:10744722
Acquisition of meiotic competence in mouse oocytes: absolute amounts of p34(cdc2), cyclin B1, cdc25C, and wee1 in meiotically incompetent and competent oocytes., PMID:11090427
BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage., PMID:11836499
Redox regulation of Cdc25C., PMID:11925443
SAPK/JNK regulates cdc2/cyclin B kinase through phosphorylation and inhibition of cdc25c., PMID:12742231
The polo box is required for multiple functions of Plx1 in mitosis., PMID:15016807
CHK1 kinase activity assay., PMID:15220526
Timing of Plk1 and MPF activation during porcine oocyte maturation., PMID:15278898
Arsenite induces prominent mitotic arrest via inhibition of G2 checkpoint activation in CGL-2 cells., PMID:15471901
Use of high-throughput protein array for profiling of differentially expressed proteins in normal and malignant breast tissue., PMID:15567944
Checkpoint kinase 1 regulates diallyl trisulfide-induced mitotic arrest in human prostate cancer cells., PMID:15961392
Zerumbone, a bioactive sesquiterpene, induces G2/M cell cycle arrest and apoptosis in leukemia cells via a Fas- and mitochondria-mediated pathway., PMID:17129359
Lidamycin induces marked G2 cell cycle arrest in human colon carcinoma HT-29 cells through activation of p38 MAPK pathway., PMID:17273739
Polo-box domains confer target specificity to the Polo-like kinase family., PMID:18359294
Differential phosphorylation of Cdc25C phosphatase in mitosis., PMID:18384749
Mechanism of cell death induced by cis-3, 4', 5-trimethoxy-3'-aminostilbene in ovarian cancer., PMID:18433847
MZ3 can induce G2/M-phase arrest and apoptosis in human leukemia cells., PMID:18491135
Arecoline, a major alkaloid of areca nut, inhibits p53, represses DNA repair, and triggers DNA damage response in human epithelial cells., PMID:18585839
Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent., PMID:18957056
Multiplexed random peptide library and phospho-specific antibodies facilitate human polo-like kinase 1 inhibitor screen., PMID:20085455
Dissecting the M phase-specific phosphorylation of serine-proline or threonine-proline motifs., PMID:20219976
JNK-mediated phosphorylation of Cdc25C regulates cell cycle entry and G(2)/M DNA damage checkpoint., PMID:20220133
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes., PMID:20500813
Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C., PMID:20530684
Distinct pools of cdc25C are phosphorylated on specific TP sites and differentially localized in human mitotic cells., PMID:20668692
KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer., PMID:21509526
Phenethyl isothiocyanate (PEITC) promotes G2/M phase arrest via p53 expression and induces apoptosis through caspase- and mitochondria-dependent signaling pathways in human prostate cancer DU 145 cells., PMID:21617228
Novel therapies in phase II and III trials for malignant pleural mesothelioma., PMID:22223868
Multiple signal transduction pathways are involved in G2/M growth arrest and apoptosis induced by the immunomodulator AS101 in multiple myeloma., PMID:22712839
Butyrate induces reactive oxygen species production and affects cell cycle progression in human gingival fibroblasts., PMID:22834967
CHK1 kinase activity assay., PMID:22941630
TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis., PMID:23456551
Prometaphase arrest-dependent phosphorylation of Bcl-2 family proteins and activation of mitochondrial apoptotic pathway are associated with 17α-estradiol-induced apoptosis in human Jurkat T cells., PMID:23707954
A novel derivative of quinazoline, WYK431 induces G2/M phase arrest and apoptosis in human gastric cancer BGC823 cells through the PI3K/Akt pathway., PMID:24859921
Galiellalactone induces cell cycle arrest and apoptosis through the ATM/ATR pathway in prostate cancer cells., PMID:26683224
A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition., PMID:27134571
JNK does not regulate meiotic progression in Xenopus oocytes: The strange case of pJNK and pERK., PMID:27297883
Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin., PMID:28335434
Heme oxygenase-1 attenuates seawater drowning-induced acute lung injury through a reduction in inflammation and oxidative stress., PMID:31254959
Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma., PMID:33321903
The Suppressing Effects of Dkk3 Expression on Aggressiveness and Tumorigenesis of Colorectal Cancer., PMID:33425757
Anti-hepatoma Effect of DC2.4 Cells Transfected with Tumor-Associated Antigen Cdc25C In Vitro., PMID:35292875
A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma., PMID:38422585
For research use only. Not for human or drug use.
